Clinical Trial Update: Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis [Phase 1]

View source ↗

Summary

Phase 1 study of EQ001 (Itolizumab) in systemic lupus erythematosus with or without active proliferative nephritis has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• EQ001 (Itolizumab) (Itolizumab)

Snippet

Sponsor: Equillium | Conditions: Lupus Erythematosus, Lupus Nephritis | Phase 1 | Status: COMPLETED | Results posted: 2025-04-18